Baxter Recalls Dextrose Bags Over Steel Particles
Baxter Healthcare recalled 70% dextrose infusion bags after the FDA identified stainless-steel particulate matter in the solution.
Baxter International (BAX) recalled Dextrose Injection, USP, 70%, 2000 mL bags after the FDA identified stainless-steel particles in the solution. The firm-initiated action was classified as Class I, with recall number D-0850-2026 and a report date of September 16, 2026.
The recalled product is Rx Only, manufactured by Baxter Healthcare Corporation in Deerfield, Illinois, and made in the United States under NDC 00338-0719-06. The FDA stated the reason as the presence of particulate matter identified as stainless-steel particles in the solution. The recall is voluntary and firm-initiated, with U.S. nationwide distribution, and the status is ongoing.
Baxter Healthcare Corporation, the recalling firm, is the Deerfield-based manufacturer named on the product. The agency’s record does not state a quantity of bags or a patient count.
The company had already been working through a string of particulate-matter Class I recalls in the weeks before this dextrose action. On August 19, 2026, Baxter Healthcare recalled Cefazolin in Dextrose, Injection, USP, 2 g / 100 mL single-dose frozen premix bags (NDC 0338-3508-41) for the presence of particulate matter, also voluntary, firm-initiated, ongoing, and distributed nationwide in the United States. On September 9, 2026, it recalled 0.9% Sodium Chloride Injection USP 500 mL VIAFLEX containers (NDC 0338-0049-03) after particulates were identified as fiberglass, again voluntary, firm-initiated, ongoing, and nationwide.
Earlier in 2024, Baxter Healthcare issued two worldwide Class I recalls of ExactaMix disposable inlets (product codes including H938173 and H938176) after increased customer reports of particulate matter in the inlet components and sterile fluid-path tubing before use. Those 2024 actions concerned compounding-device inlets rather than finished infusion bags, but they sit in the same firm-initiated, ongoing Class I pattern that the September 2026 dextrose recall extends.
The September 16 dextrose recall remains open. The FDA’s stated reason is limited to the stainless-steel particulate matter in the 70% dextrose solution; the record does not add a further health-impact description beyond the Class I classification.